NAD+ IV Therapy vs Oral NMN: Which Works Better

Sophie Chabloz on July 30, 2026

NAD+ IV Therapy vs Oral NMN: Which Works Better

By Sophie Chabloz | May 2026

NAD+ IV infusions have become the high-end ritual of the longevity world. Premium clinics offer them at €300 to €800 per session. The pitch is direct: skip the gut, deliver NAD+ straight into the bloodstream, raise levels faster than oral supplementation can. Some users swear by them. Others call them theatre. The real answer requires understanding what NAD+ does once it's in your blood, why "direct" delivery isn't the advantage it sounds like, and how IV protocols compare with consistent oral NMN over the timescales that matter. This piece sets out the comparison.

In this article:

  • What NAD+ IV therapy involves

  • The "direct delivery" assumption examined

  • What NAD+ IV does in the bloodstream

  • The cellular uptake problem

  • Cost and convenience compared

  • The case for combining (and when not to)

  • Where to go next

What NAD+ IV therapy involves

A typical NAD+ IV infusion delivers between 250 mg and 1,000 mg of NAD+ (or sometimes a precursor like NR or NMN) over a 1 to 4 hour drip. Higher doses require longer infusion times because rapid administration causes side effects: chest pressure, flushing, anxiety, intense gastrointestinal sensations.

Clinics typically administer infusions weekly, or in protocols of 5 to 10 sessions over a few weeks, then transition to monthly maintenance. Costs vary widely, from around €300 in cheaper European clinics to over €1,000 in premium US settings. The detailed comparison is at https://insights.avea-life.com/longevity/nad-injections-vs-nad-supplement-which-supports-lasting-cellular-health-better/.

The "direct delivery" assumption examined

The marketing case for IV NAD+ rests on the assumption that bypassing the gut delivers more NAD+ to your cells. This is only partially true.

Yes, IV administration achieves higher peak plasma NAD+ than oral dosing. Plasma NAD+ during an infusion can briefly reach 5 to 20 times normal baseline. That's dramatic in the short term.

But plasma NAD+ is not what your cells use. Your cells use intracellular NAD+. The relationship between the two compartments depends on cellular uptake, which is the bottleneck IV therapy doesn't actually solve.

What NAD+ IV does in the bloodstream

When NAD+ enters your bloodstream intravenously, three things happen.

First, an enzyme on the surface of immune cells called CD38 cleaves NAD+ into nicotinamide and other fragments. CD38 is the same enzyme that drives age-related NAD+ decline at the cellular level. In plasma, where NAD+ is exposed and unprotected, CD38 cleavage is rapid.

Second, a smaller fraction of NAD+ is taken up intact by certain cells through specialised transporters. The exact percentage is debated, but it's a minority of the infused dose.

Third, much of the cleaved nicotinamide is then taken up by cells through standard transporters and reassembled into NAD+ via the salvage pathway. This is the same pathway that processes oral nicotinamide or NMN.

The result: most of the "direct" NAD+ from an IV infusion isn't reaching cells as NAD+. It's being broken down to precursors and then rebuilt inside cells, the same way oral supplements work.

The cellular uptake problem

The fundamental challenge for any NAD+ supplementation strategy is getting NAD+ across the cell membrane. NAD+ is a large, polar molecule. It doesn't diffuse easily through lipid bilayers. Cells have to actively transport it in.

The transporters that move NAD+ (and its precursors) are present in limited density. They saturate at relatively modest plasma concentrations. Above saturation, additional NAD+ in the blood doesn't enter cells more efficiently. It just circulates and gets degraded.

This is why oral NMN at 250-500 mg per day produces meaningful intracellular NAD+ elevation despite delivering far less total NAD+ than an IV infusion. The oral route delivers a steady, transporter-friendly load. The IV route delivers an overwhelming spike that the cellular machinery can't fully utilise.

The Pencina et al. 2023 trial found that the benefits didn't scale indefinitely with dose across 300, 600, and 900 mg: past a point, more wasn't clearly better. The same logic applies to IV: above transporter saturation, more is just more circulating molecule, not more cellular function.

Cost and convenience compared

A practical comparison over a typical 3-month protocol.

NAD+ IV protocol (weekly for 12 weeks): roughly €4,000 to €10,000 depending on the clinic. Twelve clinic visits requiring 1 to 4 hours each. Side effects (chest pressure, flushing, GI symptoms) common during infusions.

Oral NMN protocol (250-500 mg daily for 12 weeks): roughly €120 to €240 for a 3-month supply of quality NMN. No clinic visits. No infusion side effects. Mild GI symptoms in a small percentage of users, comparable to placebo in trials.

The comparison gets more lopsided over time. A multi-year IV protocol costs in the tens of thousands. A multi-year oral NMN protocol costs hundreds.

The functional-outcomes data we have favour sustained oral supplementation over intermittent IV. Yoshino et al. 2021, Pencina et al. 2023, and Igarashi et al. 2022 all used oral protocols and reported meaningful NAD+ elevation and functional improvements. The IV NAD+ literature, by contrast, is dominated by case reports, observational data from clinics, and short-duration studies without comparator groups.

The case for combining (and when not to)

There are situations where IV NAD+ has a defensible place, and situations where it doesn't.

NAD+ IV therapy is used in some clinical settings, always under medical supervision. If you're dealing with a specific medical condition, that's a conversation to have with your doctor rather than a decision to self-direct, and this article isn't the place for it. What we can compare here is the everyday case: a healthy adult addressing the gradual NAD+ decline that comes with age.

For that person, if you can afford the cost and want the experience of a clinical longevity protocol, IV NAD+ isn't harmful. It's expensive and inefficient relative to oral, but it's generally well-tolerated when administered properly.

What the evidence does not support is replacing oral NMN with periodic IV infusions as a primary strategy for age-related NAD+ decline. The economics are unfavourable, the cellular uptake is similar in mechanism, and the functional-outcomes data favour sustained oral supplementation.

For most people pursuing an evidence-based approach to NAD+ restoration, the practical answer is: AVEA NMN at 250-500 mg per day, taken in the morning, for the first three months. Test your intracellular NAD+ at the start and at week 8-12 to confirm response. If you also want to try IV NAD+, treat it as an adjunct to a sustained oral protocol rather than a replacement.

Where to go next

If you want the cellular logic that underlies this comparison, "What is NAD+ and why it declines with age" covers the biochemistry. If you're settling on a starting NMN dose, "NMN dosage: 250 mg vs 500 mg vs higher amounts" covers the dose-response evidence. And "NAD+ Decline and How to Restore It" brings the broader picture together.

Related reading from AVEA insights